[Effictiveness and safety of Xueshuantong Injection in treatment of unstable angina pectoris: a systematic review and Meta-analysis of randomized controlled trials].

To assess the effectiveness and safety of Xueshuantong Injection in the treatment of unstable angina pectoris. Literatures were retrieved in PubMed,the Cochrane Library,EMbase,the China National Knowledge Infrastructure Database( CNKI),the Chongqing VIP Chinese Science Database( VIP),the Chinese Biomedical Literature Database( Sino Med) and Wanfang Data. The time limitation ranged from the commencement of each database to April 28,2019. The assessment of ethodological quality was based on the Cochrane Handbook 5.1,and the data were analyzed by using Rev Man 5.3 software. A total of 38 RCTs involving 4 074 patients were included. The included trials were all of low quality. Xueshuantong Injection combined with routine basic treatment( RBT) was superior to RBT alone in alleviating clinical symptoms,with statistically significant differences between the groups( RR = 1. 19,95% CI[1. 15,1. 24]). Xueshuantong Injection combined with RBT was better than RBT alone in the efficiency of anginal symptom( RR = 1.23,95%CI[1.18,1.29]). Xueshuantong Injection combined with RBT reduced the consumption of nitroglycerin,which was more effectively than RBT alone,with statistically significant differences between the groups( RR = 1.64,95%CI[1.23,2.19]). Xueshuantong Injection combined with RBT decreased hs-CRP levels,which was more effectively than RBT alone,with statistically significant differences between the groups( MD =-0.48,95%CI[-0.57,-0.40]). However,there was no statistical difference between groups in the incidence of myocardial infarction. The reported adverse effects of Xueshuantong Injection were mainly dizziness,headache,itchy skin and gastrointestinal symptoms. Xueshuantong Injection combined with RBT can alleviate unstable angina pectoris. However,due to the low quality of included studies,further well-designed multicenter and large-scale RCTs are still needed to evaluate the efficacy of Xueshuantong Injection.